<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2572">
  <stage>Registered</stage>
  <submitdate>12/11/2009</submitdate>
  <approvaldate>12/11/2009</approvaldate>
  <nctid>NCT01014247</nctid>
  <trial_identification>
    <studytitle>Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation</studytitle>
    <scientifictitle>A Randomized, Double-blind, 2-way Crossover, Placebo-controlled Study to Investigate the Influence of a Single-dose of Moxifloxacin on the QTc Interval in Healthy Male and Female Subjects for Positive Control Validation in Selected Centers of the PATENT-1 Trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2009-012363-34</secondaryid>
    <secondaryid>13796</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>QTc Evaluation</healthcondition>
    <healthcondition>Electrocardiography</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Avelox (Moxifloxacin, BAY12-8039)
Treatment: drugs - Placebo

Active Comparator: Arm 1 - 

Placebo Comparator: Arm 2 - 


Treatment: drugs: Avelox (Moxifloxacin, BAY12-8039)
Single dose of 400 mg

Treatment: drugs: Placebo
Single dose of matching tablet

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>QTc interval at 3 hours</outcome>
      <timepoint>Day 1 of treatment period 1 and 2</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety variables - Adverse events, clinical laboratory, vital signs, ECG findings</outcome>
      <timepoint>Up to last visit of follow up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic parameters - Cmax, Cmax,norm, tmax</outcome>
      <timepoint>On different time points</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy volunteers

          -  Age 18-75 years - Normal ECG</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Abnormal ECG - Intolerance to fluorochinolones</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>56</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to investigate the effect of moxifloxacin on the QT interval in
      order to gain information on the validity of results that will be collected during another
      clinical study testing riociguat in patients with pulmonary arterial hypertension (PATENT-1
      study).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01014247</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>